NASDAQ · GANX
Healthcare · Biotechnology
$2.01
Up+$0.03 (+1.26%)
Updated Aug 22, 2026, 5:28 PM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
GANX closed at $2.01 after 21 trading sessions, up 14.57% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $2.00 | $2.045 | $1.98 | $2.005 | 277.48K |
| Aug 20, 2026 | $2.03 | $2.035 | $1.95 | $1.98 | 382.53K |
| Aug 19, 2026 | $2.02 | $2.085 | $2.02 | $2.07 | 300.04K |
| Aug 18, 2026 | $2.02 | $2.06 | $1.965 | $2.03 | 351.57K |
| Aug 17, 2026 | $2.11 | $2.15 | $2.03 | $2.04 | 323.49K |
| Aug 14, 2026 | $2.16 | $2.1863 | $2.09 | $2.12 | 519K |
| Aug 13, 2026 | $2.15 | $2.37 | $2.135 | $2.165 | 1.33M |
| Aug 12, 2026 | $2.01 | $2.17 | $2.01 | $2.12 | 586.88K |
| Aug 11, 2026 | $1.78 | $2.14 | $1.78 | $2.06 | 1.67M |
| Aug 10, 2026 | $1.82 | $1.84 | $1.76 | $1.77 | 282.96K |
| Aug 7, 2026 | $1.80 | $1.85 | $1.78 | $1.82 | 342.93K |
| Aug 6, 2026 | $1.78 | $1.855 | $1.73 | $1.78 | 371.94K |
| Aug 5, 2026 | $1.78 | $1.8299 | $1.76 | $1.80 | 297.5K |
| Aug 4, 2026 | $1.74 | $1.80 | $1.70 | $1.76 | 282.57K |
| Aug 3, 2026 | $1.67 | $1.77 | $1.66 | $1.75 | 390.86K |
| Jul 31, 2026 | $1.76 | $1.78 | $1.68 | $1.68 | 230.68K |
| Jul 30, 2026 | $1.70 | $1.79 | $1.66 | $1.76 | 696.28K |
| Jul 29, 2026 | $1.74 | $1.765 | $1.68 | $1.69 | 542.61K |
| Jul 28, 2026 | $1.85 | $1.85 | $1.715 | $1.73 | 325.17K |
| Jul 27, 2026 | $1.79 | $1.89 | $1.769 | $1.86 | 396.22K |
| Jul 24, 2026 | $1.81 | $1.81 | $1.7399 | $1.75 | 471.96K |
The latest Smart Investors Daily articles mentioning GANX.
GANX research
Company profile and research snapshot.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 11, 2026 | BTIG | Buy | — |
| Jul 1, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 30, 2026 | BTIG | Buy | — |
| Dec 19, 2025 | HC Wainwright & Co. | Buy | — |
| Oct 15, 2025 | BTIG | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 11, 2026
Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 42.11 percent increase over losses of $(0.19) per share
Benzinga · Jul 16, 2026
To our valued Shareholders,As we progress through 2026 and look ahead to delivering continued significant progress, I want to thank you for your steadfast support of Gain Therapeutics. The year has been one of
Benzinga · Jul 1, 2026
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.
Benzinga · Jun 29, 2026
IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26FDA’s decision follows positive Phase 1 results for GT-02287 in both healthy volunteers and people
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GANX.
